EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID

Samuel B K Keat, Priyanka Khatri, Youssif M Ali, Chanuka H Arachchilage, Gregory Demopulos, Kirsten Baillie, Kelly L Miners, Kristin Ladell iD, Samantha A Jones, Helen E Davies, David A Price iD, Wioleta M Zelek und 3 weitere

Immunology · 2026

DOI: 10.1111/imm.70110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, 2026. Verfasst von Samuel B K Keat und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK. Hauptthemen laut MEDLINE: COVID-19, Complement Pathway, Mannose-Binding Lectin, SARS-CoV-2, Complement Activation. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Dementia Research Institute, National Institute for Health and Care Research, Omeros Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long COVID affects a substantial proportion of survivors of acute infection with severe acute respiratory syndrome‐associated coronavirus‐2 (SARS‐CoV‐2), who suffer a variety of symptoms that limit their quality of life and economic activity. Although the aetiology of long COVID is obscure, it appears to be a chronic inflammatory condition. Complement dysregulation is a prevalent feature of long COVID. Specifically, markers of classical, alternative, and terminal pathway activation are often elevated in patients with this condition. Here, we used a sensitive assay for mannan‐binding lectin‐associated serine protease‐2 (MASP‐2)/C1Inh complexes to analyse lectin pathway activation in a previously characterised cohort of patients with long COVID ( n = 159) and healthy convalescent individuals with no persistent symptoms after infection with SARS‐CoV‐2 ( n = 76). The data were combined with those from the most predictive complement analytes identified previously to delineate potential biomarkers of long COVID. MASP‐2/C1Inh complexes were significantly elevated in patients with long COVID ( p = 0.0003). Generalised linear modelling further identified an optimal set of four markers, namely iC3b (alternative pathway), TCC (terminal pathway), MASP‐2/C1Inh (lectin pathway), and the complement regulator properdin, which had a receiver operating characteristic predictive power of 0.796 (95% confidence interval = 0.664–0.905). Combinations of the classical pathway markers C4, C1q, and C1s/C1Inh were poorly predictive of long COVID. These findings demonstrate that activation of the lectin complement pathway, which occurs upstream of the alternative and terminal pathways and can be inhibited therapeutically, is a salient feature of long COVID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Complement Pathway, Mannose-Binding LectinSARS-CoV-2Complement ActivationLectinsHumansMannose-Binding Protein-Associated Serine ProteasesPost-Acute COVID-19 SyndromeFemaleMaleBiomarkersMiddle AgedAgedAdult

Stichwörter der Autor:innen

complementinflammationlectin pathwaylong COVIDtherapeutics

Substanzen

Mannose-Binding Protein-Associated Serine ProteasesMASP2 protein, humanBiomarkersLectins

Autor:innen und Institutionen

  • Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK.
  • Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.
  • Department of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
  • Omeros Corporation, Seattle, Washington, USA.
  • Department of Respiratory Medicine, University Hospital Llandough, Penarth, UK.
  • Systems Immunity Research Institute, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, UK.

ORCID-Profile: Kristin Ladell, David A Price, Nicholas J Lynch

Förderung

  • UK Dementia Research Institute
  • National Institute for Health and Care Research
  • Omeros Corporation
  • PolyBio Research Foundation
  • Race against Dementia Alzheimer's Research

Zitieren

APA

Keat, S. B. K., Khatri, P., Ali, Y. M., Arachchilage, C. H., Demopulos, G., Baillie, K., Miners, K. L., Ladell, K., Jones, S. A., Davies, H. E., Price, D. A., Zelek, W. M., Morgan, B. P., Schwaeble, W. J., & Lynch, N. J. (2026). Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID. Immunology. https://doi.org/10.1111/imm.70110

Vancouver

Keat SBK, Khatri P, Ali YM, Arachchilage CH, Demopulos G, Baillie K, et al. Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID. Immunology. 2026. doi:10.1111/imm.70110

BibTeX
@article{Keat2026,
  author = {Keat, Samuel B K and Khatri, Priyanka and Ali, Youssif M and Arachchilage, Chanuka H and Demopulos, Gregory and Baillie, Kirsten and Miners, Kelly L and Ladell, Kristin and Jones, Samantha A and Davies, Helen E and Price, David A and Zelek, Wioleta M and Morgan, B Paul and Schwaeble, Wilhelm J and Lynch, Nicholas J},
  title = {Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID},
  journal = {Immunology},
  year = {2026},
  doi = {10.1111/imm.70110}
}
Kostenlos starten →